Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Sea Limited (SE) Price & Performance

Eli Lilly And CoTrade
Sea LimitedTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Sea Limited — how do they compare? Eli Lilly And Co trades at $1,204.02 (market cap $1.08T), while Sea Limited trades at $127.62 (market cap $80.55B). The key difference: Eli Lilly And Co is far larger — about 13.4× Sea Limited's market cap, and Eli Lilly And Co pays a 0.57% dividend while Sea Limited pays none. Which is the better fit depends on your goals.

LLYSE
Market Cap
$1.08T$80.55B
Sector
HealthMedia
52-Week High
$1.24K$196.50
52-Week Low
$639.43$78.16
Enterprise Value
$1.13T$75.58B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Sea Limited

Sea Limited (SE) trades at $114.80, up 1.21% with strong technical momentum as the stock approaches key resistance levels. The company demonstrates robust fundamental growth with Q2 2026 revenue of $7.8 billion (up 48% YoY) and net income growth of 11%, supported by diversified performance across e-commerce, fintech, and gaming segments. Analyst consensus remains strongly bullish with a $128.33 price target, though valuation metrics appear elevated with a P/E of 50.78.

SE presents compelling growth prospects with accelerating revenue and expanding profitability, but faces risks from increased investment spending and competitive pressures. The stock's current technical overbought condition near resistance suggests potential near-term consolidation before further upside. Wall Street's overwhelming buy rating (70% of analysts) supports the positive long-term outlook despite premium valuation concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Sea Limited

Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.

Read more on SE